Q2 2025 Bristol-Myers Squibb Co Earnings Call Transcript
Key Points
- Bristol-Myers Squibb Co (BMY) reported a 17% year-over-year increase in sales for its growth portfolio, driven by strong demand across key brands.
- The company secured regulatory approvals in Europe for OPDIVO in neoadjuvant lung cancer and Qvantig across multiple solid tumor indications.
- Strategic partnerships with BioNTech and Philochem were announced to expand BMY's immuno-oncology leadership and strengthen its radiopharmaceutical business.
- BMY raised its top-line and bottom-line guidance for the year, reflecting strong performance and positive feedback from recent product launches like COBENFY and Qvantig.
- The company is entering a data-rich period with expectations for seven registration assets and seven meaningful life cycle management opportunities over the next 12 to 24 months.
- Some studies did not meet expectations, although BMY stated these have limited impact on long-term growth.
- The company faces macro pressures and industry challenges, including the need to navigate complex regulatory environments and potential competition.
- There are concerns about the sustainability of spending relative to sales, with ongoing investments in growth and development programs.
- Competitive dynamics in the market, such as the potential entry of a second myosin inhibitor, could impact the growth trajectory of products like Camzyos.
- BMY's legacy portfolio is expected to decline by 15% to 17% for the year, which could impact overall revenue growth.
Good day, and welcome to the Bristol-Myers Squibb second-quarter 2025 earnings conference call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Mr. Chuck Triano, Senior Vice President and Head of Investor Relations. Please go ahead, sir.
Thank you, and good morning, everyone. We appreciate you joining our second-quarter 2025 earnings call.
Joining me this morning with prepared remarks are Chris Boerner, our Board Chair and Chief Executive Officer; and David Elkins, our Chief Financial Officer. Also participating in today's call are Adam Lenkowsky, our Chief Commercialization Officer; and Samit Hirawat, our Chief Medical Officer and Head of Global Drug Development. Earlier this morning, we posted our quarterly slide presentation to bms.com that you can use to follow along with Chris and David's remarks.
Before we get started, I'll remind everybody that during this call, we will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
